Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes
Article first published online: 8 FEB 2006
Copyright © 2006 John Wiley & Sons, Ltd.
Rapid Communications in Mass Spectrometry
Volume 20, Issue 5, pages 870–876, 15 March 2006
How to Cite
Thevis, M., Kamber, M. and Schänzer, W. (2006), Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes. Rapid Commun. Mass Spectrom., 20: 870–876. doi: 10.1002/rcm.2389
- Issue published online: 8 FEB 2006
- Article first published online: 8 FEB 2006
- Manuscript Revised: 10 JAN 2006
- Manuscript Accepted: 10 JAN 2006
- Manuscript Received: 15 DEC 2005
Anabolic agents have been among the most frequently detected drugs in amateur and professional sport. A novel class of therapeutics presumably complementing anabolic steroids in the near future includes so-called selective androgen receptor modulators (SARMs) that have been under clinical investigations for several years. Although not yet commercially available, their potential for misuse in sports is high. Four aryl-propionamide-derived SARMs were synthesized in order to establish a fast and robust screening procedure using liquid chromatography/electrospray ionization tandem mass spectrometry. Synthesized compounds were characterized by high-resolution/high-accuracy mass analysis employing a linear ion trap-Orbitrap hybrid mass spectrometer while routine analyses were conducted on a triple-quadrupole mass spectrometer. Characteristic product ions obtained by collision-induced dissociation were found at m/z 289 and 261 as well as m/z 269 and 241 representing the bisubstituted aniline residues of selected model compounds. Assay validation was performed regarding lower limit of detection (1 ng/mL), recovery (85–105%), intraday precision (7.6–11.6%) and interday precision (9.9–14.4%), and precursor ion scan experiments on diagnostic product ions enabled the detection of a structurally related compound at 50 ng/mL. Copyright © 2006 John Wiley & Sons, Ltd.